GHIT Fund Global Health Innovative Technology Fund

Investment

Investment Overview

Investment to Date

Since 2013

Breakdown

Disease
Total : 1000
（USD 1.00 = JPY 100）
Malaria $5,356,668,398 (40.6%)
Tuberculosis $5,356,668,398 (40.6%)
NTDs $5,356,668,398 (40.6%)
Intervention
Total : 1000
（USD 1.00 = JPY 100）
Drugs $5,356,668,398 (40.6%)
Vaccines $5,356,668,398 (40.6%)
Diagnostics $5,356,668,398 (40.6%)
Development
Stage
Total : 1000
（USD 1.00 = JPY 100）
Discovery $5,356,668,398 (40.6%)
Preclinical $5,356,668,398 (40.6%)
Clinical $5,356,668,398 (40.6%)

GHIT invests using Japanese yen. US dollar amounts represent conversions from Japanese yen, solely for the reader’s convenience, at JPY 100 = USD 1.

Every project is counted as a single investment, even if it has received multiple rounds of GHIT funding.

Due to rounding, total percentages under each category may not add up precisely to 100.
For projects that span across multiple GHIT investment platforms (i.e., programs that transition from one platform to the other), the total investment amount is shown based on the project's most current development status.

Find an Investment​

Check All Clear All

Each awarded project is listed once, regardless of whether it has received multiple investments from GHIT.
Development stage categories are as follows:

Drugs and Vaccines
Discovery: From Target Research to Hit-to-Lead ｜ Preclinical: Preclinical Development｜ Clinical: From Phase I to Registration

Diagnostics
Discovery: Target Research｜Preclinical: Product Design｜Clinical: From Product Development to Registration

Create Excel File
 
Development Stage Current Stage Disease Intervention RFP Year Status Project Partner Awarded Amount Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $104,264 Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $73,940 Details
Discovery Drug Hit Identification Malaria Drug 2013 COMPLETE Screening Program Kitasato Institute,Medicines for Malaria Venture (MMV) $570 Details
Discovery Drug Hit Identification Malaria Drug 2013 TERMINATED Screening Program Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $241,372 Details
Discovery Drug Hit Identification Malaria Drug 2013 TERMINATED Screening Program Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV) $11,286 Details
Discovery Drug Hit Identification Malaria Drug 2014 COMPLETE Screening Program Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV) $186,420 Details
Discovery Drug Hit Identification Malaria Drug 2014 COMPLETE Screening Program Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV) $137,883 Details
Discovery Drug Lead Identification Malaria Drug 2014 COMPLETE Design and Cost-effective de novo Synthesis of Aza-artemisinins Hokkaido University,Kitasato Institute,Medicines for Malaria Venture (MMV) $60,000 Details
Discovery Drug Lead Identification Malaria Drug 2014 TERMINATED Identification of lead compounds for anti-Malarial agent Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $636,941 Details
Discovery Drug Lead Identification Malaria Drug 2015 COMPLETE Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $779,760 Details
Discovery Drug Lead Identification Malaria Drug 2015 COMPLETE Antimalarial hits from whole cell screening Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $764,033 Details
Discovery Drug Target Validation Malaria Drug 2015 COMPLETE Proteasome inhibitors as new potent resistance-­reversing antimalarials The University of Melbourne,Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $297,133 Details
Discovery Drug Hit Identification Malaria Drug 2015 COMPLETE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV) $150,000 Details
Discovery Drug Hit Identification Malaria Drug 2015 COMPLETE Screening Program Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV) $68,400 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $750,000 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE Mitsubishi Tanabe malaria Hit-to-Lead Medicines for Malaria Venture (MMV),Mitsubishi Tanabe Pharma Corporation $618,222 Details
Discovery Drug Lead Identification Malaria Drug 2016 COMPLETE New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $483,360 Details
Discovery Drug Lead Identification Malaria Drug 2017 COMPLETE HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute $461,245 Details
Discovery Drug Lead Identification Malaria Drug 2017 COMPLETE New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma Medicines for Malaria Venture (MMV),Sumitomo Dainippon Pharma Co., Ltd. $445,500 Details
Discovery Drug Hit Identification Malaria Drug 2017 COMPLETE Screening Program Astellas Pharma Inc.,Medicines for Malaria Venture (MMV) $65,836 Details
Discovery Drug Hit Identification Malaria Drug 2017 COMPLETE Screening Program Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $49,500 Details
Discovery Drug Lead Identification Malaria Drug 2018 COMPLETE New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $528,000 Details
Discovery Drug Hit Identification Malaria Drug 2018 COMPLETE Screening Program Medicines for Malaria Venture (MMV),University of Tokyo $150,000 Details
Discovery Drug Lead Identification Malaria Drug 2019 COMPLETE Development of nucleoside sulfamates as novel antimalarials The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,016,129 Details
Discovery Drug Lead Identification Malaria Drug 2019 COMPLETE Proteasome inhibitors as new potent antimalarials The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $526,140 Details
Discovery Drug Hit Identification Malaria Drug 2019 COMPLETE Screening project between Takeda and MMV Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $41,962 Details
Discovery Drug Lead Identification Malaria Drug 2020 ACTIVE Hit-to-lead development of new antimalarial compounds from DDI library University of Tokyo,Medicines for Malaria Venture (MMV) $1,167,442 Details
Discovery Drug Hit Identification Malaria Drug 2020 ACTIVE Pioneering antisense oligonucleotides as long-acting malaria prophylactics University of California, San Diego (UCSD),Eisai Co., Ltd. $922,972 Details
Discovery Drug Hit Identification Malaria Drug 2020 ACTIVE Screening Program Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited,Eisai Co., Ltd.,Daiichi Sankyo, Inc. $210,936 Details
Discovery Drug Lead Identification Malaria Drug 2020 COMPLETE Prolyl tRNA Synthetase Inhibitors for New Antimalarials Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $547,268 Details
Discovery Drug Hit Identification Malaria Drug 2020 COMPLETE Screening Program Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $122,013 Details
Discovery Drug Lead Identification Malaria Drug 2021 ACTIVE Hit-to-Lead development of novel Astellas compounds with antimalarial activity TCG Lifesciences Private Limited. (TCGLS),Astellas Pharma Inc.,Medicines for Malaria Venture (MMV) $1,317,435 Details
Discovery Drug Target Identification Malaria Drug 2021 ACTIVE Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform National Center for Genetic Engineering and Biotechnology (BIOTEC) ,FIMECS, Inc. $838,587 Details
Discovery Drug Lead Identification Malaria Drug 2022 ACTIVE A Hit-to-Lead study of screening hits for novel antimalarial compounds SHIONOGI & CO., LTD.,Nagasaki University,Medicines for Malaria Venture (MMV) $1,323,184 Details
Discovery Drug Lead Identification Malaria Drug 2022 ACTIVE Irresistible series as anti-malarial agent Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,307,233 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2013 COMPLETE Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach PATH Malaria Vaccine Initiative,Ehime University,CellFree Sciences Co. Ltd. $591,396 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2014 COMPLETE Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate PATH Malaria Vaccine Initiative,Ehime University $766,098 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2016 COMPLETE A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display PATH Malaria Vaccine Initiative,Ehime University $595,650 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2017 COMPLETE Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator The Pennsylvania State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc. $881,900 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2019 COMPLETE Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine PATH Malaria Vaccine Initiative,Ehime University,University at Buffalo, The State University of New York $972,951 Details
Discovery Vaccine Technology Platform Identification Malaria Vaccine 2019 COMPLETE Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity Mahidol University,Tokyo Medical and Dental University,University of Pennsylvania $960,771 Details
Discovery Vaccine Vaccine Concept Development Malaria Vaccine 2019 COMPLETE Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants Kanazawa University,Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge $526,900 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2020 COMPLETE Evaluation of a malaria vaccine candidate comprised of full-length recombinant CSP formulated with SA-1 adjuvant, using RTS,S/AS01 as a benchmark PATH,Sumitomo Dainippon Pharma Co., Ltd.,Ehime University $999,733 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2021 ACTIVE Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking Kanazawa University,Hokkaido University,Jichi Medical University,Kyoto University,Toyama University,University of Cambridge,Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) $698,170 Details
Discovery Vaccine Antigen Identification Malaria Vaccine 2022 ACTIVE Development of a potent Pvs230 mRNA vaccine to block transmission of P. vivax Mahidol University,Ehime University $699,652 Details
Discovery Diagnostic Technical Feasibility Malaria Diagnostic 2015 COMPLETE Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination The Walter and Eliza Hall Institute of Medical Research,Proteo-Science Centre, Ehime University,CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND) $993,030 Details
Discovery Diagnostic Concept Development Malaria Diagnostic 2017 COMPLETE Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre $728,830 Details
Discovery Diagnostic Technical Feasibility Malaria Diagnostic 2020 ACTIVE Towards the rapid diagnosis of malaria hypnozoite infection: feasibility studies Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Biomedical Primate Research Centre,National Institute of Technology, Kumamoto College $999,809 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 COMPLETE Screening Program SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development $105,450 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development $55,550 Details
Discovery Drug Hit Identification Tuberculosis Drug 2013 TERMINATED Screening Program Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development $135,300 Details
Discovery Drug Hit Identification Tuberculosis Drug 2014 COMPLETE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2014 TERMINATED Screening Program Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 COMPLETE Hit-to-Lead Development of anti-TB Phenotypic Screening Hits SHIONOGI & CO., LTD.,The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development $999,720 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 COMPLETE Development of Phenotypic Screening Hits against Mycobacterium tuberculosis Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development $792,165 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program HYPHAGENESIS INC.,Toyama Prefectural University,The Global Alliance for TB Drug Development $150,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Mitsubishi Tanabe Pharma Corporation,The Global Alliance for TB Drug Development $132,000 Details
Discovery Drug Hit Identification Tuberculosis Drug 2015 COMPLETE Screening Program Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development $79,200 Details
Discovery Drug Lead Identification Tuberculosis Drug 2015 TERMINATED Identification of lead compounds as novel anti‐TB agents Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development $908,231 Details
Discovery Drug Target Validation Tuberculosis Drug 2016 COMPLETE Host-directed drug targeting against tuberculosis RIKEN,International Centre for Genetic Engineering and Biotechnology $204,990 Details
Discovery Drug Hit Identification Tuberculosis Drug 2017 COMPLETE Screening Program Astellas Pharma Inc.,The Global Alliance for TB Drug Development $99,986 Details
Discovery Drug Lead Identification Tuberculosis Drug 2018 ACTIVE Hit-to-Lead Development of Novel anti-TB Natural Products Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $1,192,440 Details
Discovery Drug Hit Identification Tuberculosis Drug 2018 TERMINATED Screening Program The Global Alliance for TB Drug Development,Fujifilm Corporation $110,000 Details
Discovery Drug Lead Identification Tuberculosis Drug 2019 COMPLETE Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits The Global Alliance for TB Drug Development,Takeda Pharmaceutical Company Limited $1,112,058 Details
Discovery Drug Lead Identification Tuberculosis Drug 2019 COMPLETE Hit-to-Lead Development of Phenotypic Screening Hits The Global Alliance for TB Drug Development,Chugai Pharmaceutical Co., Ltd. $953,159 Details
Discovery Drug Target Identification Tuberculosis Drug 2020 ACTIVE Identification of novel dual-acting bactericidal drug targets against Mycobacterium tuberculosis Fujita Health University ,Research Institute of Tuberculosis ,Nagoya University,Hokkaido University,Harvard University,University of Minnesota $974,619 Details
Discovery Drug Lead Identification Tuberculosis Drug 2020 COMPLETE Hit-to-Lead Development of Hits Identified in the Phenotypic Screening against Mycobacterium tuberculosis (Mtb) The Global Alliance for TB Drug Development,Astellas Pharma Inc. $801,363 Details
Discovery Drug Hit Identification Tuberculosis Drug 2020 COMPLETE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $118,300 Details
Discovery Drug Hit Identification Tuberculosis Drug 2022 ACTIVE Screening project between Daiichi Sankyo RD Novare and TB Alliance Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development $152,970 Details
Discovery Vaccine Vaccine Concept Development Tuberculosis Vaccine 2016 COMPLETE Development of a new mucosal vaccine for Tuberculosis using antibody engineering Universiti Sains Malaysia,University of Tokyo,Instituto de Nutricion “Salvador Zubiran”,Universidad de Concepcion $373,561 Details
Discovery Diagnostic Concept Development Tuberculosis Diagnostic 2018 COMPLETE Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria. Asahi Kasei Corporation,Biopromic AB $1,000,000 Details
Discovery Drug Lead Identification NTD (Chagas disease) Drug 2013 COMPLETE Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease Broad Institute,Eisai Co., Ltd. $500,000 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $75,582 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative $75,582 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 COMPLETE Screening Program Kitasato Institute,Drugs for Neglected Diseases initiative $0 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2013 TERMINATED Screening Program Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative $7,558 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2014 COMPLETE Neglected Tropical Diseases Drug Discovery Booster Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited $795,437 Details
Discovery Drug Hit Identification NTD (Chagas disease) Drug 2015 COMPLETE Screening Program Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $210,050 Details
Discovery Drug Hit Identification NTD (Leishmaniasis) Drug 2015 TERMINATED Screening Program Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $31,000 Details
Discovery Drug Target Validation NTD (Chagas disease / Leishmaniasis) Drug 2016 COMPLETE Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis RIKEN,Structural Genomics Consortium at University of Toronto,The University of Melbourne,McGill University ,Medicines for Malaria Venture (MMV),Drugs for Neglected Diseases initiative $982,436 Details
Discovery Drug Lead Identification NTD (Chagas disease) Drug 2016 COMPLETE Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $780,000 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2016 COMPLETE Neglected Tropical Diseases Drug Discovery Booster II Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited $549,447 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2017 COMPLETE Neglected Tropical Diseases Drug Discovery Booster III Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Astellas Pharma Inc. $1,498,328 Details
Discovery Drug Target Validation NTD (Chagas disease) Drug 2017 COMPLETE Target determination and exploratory research for discovery of new drugs against Chagas disease. Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Advanced Industrial Science and Technology,High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM) $882,350 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2017 COMPLETE Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare Drugs for Neglected Diseases initiative,Daiichi Sankyo RD Novare Co., Ltd. $119,000 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2019 COMPLETE Screening project between Mitsubishi Tanabe and DNDi Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative $150,000 Details
Discovery Drug Target Identification NTD (Chagas disease) Drug 2020 ACTIVE Target validation and AI-guided identification of Trypanosoma cruzi phosphodiesterase inhibitors for the treatment of Chagas disease Eisai Co., Ltd.,Universidad Nacional de La Plata (UNLP) $710,077 Details
Discovery Drug Hit Identification NTD (Leishmaniasis) Drug 2020 ACTIVE Screening Program University of Tokyo,Drugs for Neglected Diseases initiative $168,759 Details
Discovery Drug Lead Identification NTD (Chagas disease / Leishmaniasis) Drug 2020 COMPLETE Hit-To-Lead development for Neglected Tropical Diseases Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative $1,170,663 Details
Discovery Drug Lead Identification NTD (Soil-transmitted helminthiasis) Drug 2020 COMPLETE Cry5B optimization for Trichuris - whipworm PATH,Kao Corporation,University of Massachusetts Medical School $923,020 Details
Discovery Drug Hit Identification NTD (Chagas disease / Leishmaniasis) Drug 2020 COMPLETE Screening Program Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative $80,000 Details
Discovery Drug Target Identification NTD (Chagas disease) Drug 2021 ACTIVE Autophagy as a novel drug-development target for Chagas disease National Institute of Advanced Industrial Science and Technology,Drugs for Neglected Diseases initiative $989,200 Details
Discovery Drug Hit Identification NTD (Chagas disease) Drug 2021 ACTIVE Screening project between Daiichi Sankyo Company Limited and DNDi Drugs for Neglected Diseases initiative,Daiichi Sankyo, Inc. $109,763 Details
Discovery Drug Hit Identification NTD (Chagas disease) Drug 2021 ACTIVE Screening project between Takeda Pharmaceutical Company Ltd. and DNDi Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited $89,946 Details
Discovery Diagnostic Development Feasibility NTD (Schistosomiasis) Diagnostic 2014 COMPLETE Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine,Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines $779,036 Details
Discovery Diagnostic Concept Development NTD (Schistosomiasis) Diagnostic 2017 COMPLETE Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine Lygature,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center $763,890 Details
Discovery Diagnostic Concept Development NTD (Mycetoma) Diagnostic 2019 COMPLETE MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma RIKEN,Erasmus University Medical Center,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum $285,937 Details
Discovery Diagnostic Concept Development NTD (Buruli ulcer) Diagnostic 2020 COMPLETE Development of ‘all-in-one’ diagnostic kit for Buruli ulcer using lateral flow DNA-chromatography Teikyo University,Keio University School of Medicine,TBA Co., Ltd.,Fasmac Co., Ltd.,Raoul Follereau Institute Côte d’Ivoire,Institut Pasteur de Côte d'Ivoire,Hope Commission International,Nagasaki University $895,584 Details
Preclinical Drug Preclinical development Malaria Drug 2013 TERMINATED Development of ELQ300 as a long acting antimalarial Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $560,000 Details
Preclinical Drug Preclinical development Malaria Drug 2014 COMPLETE Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4 St. Jude Children’s Research Hospital,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $3,768,922 Details
Preclinical Drug Lead Optimization Malaria Drug 2014 COMPLETE Lead optimization of a novel mechanism-of-action antimalarial Broad Institute,Eisai Co., Ltd. $2,997,525 Details
Preclinical Drug Lead Optimization Malaria Drug 2015 COMPLETE E209 a tetraoxane based rapidly acting antimalarial – candidate selection Liverpool School of Tropical Medicine,University of Liverpool,Eisai Co., Ltd. $207,753 Details
Preclinical Drug Lead Optimization Malaria Drug 2016 COMPLETE Development of a novel mechanism-of-action antimalarial drug with multistage activity Broad Institute,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $1,999,993 Details
Preclinical Drug Preclinical development Malaria Drug 2016 TERMINATED DSM421 Clinical Development up to phase IIa GO Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $7,499,822 Details
Preclinical Drug Lead Optimization Malaria Drug 2016 TERMINATED Identification of pre-clinical candidate as an anti-malarial agent Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV) $1,761,309 Details
Preclinical Drug Lead Optimization Malaria Drug 2017 COMPLETE Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $2,639,670 Details
Preclinical Drug Lead Optimization Malaria Drug 2018 ACTIVE Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria Broad Institute,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $4,214,187 Details
Preclinical Drug Lead Optimization Malaria Drug 2018 COMPLETE Mitsubishi Tanabe Lead Optimization of Anti-Malarials Medicines for Malaria Venture (MMV),Mitsubishi Tanabe Pharma Corporation $1,922,475 Details
Preclinical Drug Preclinical development Malaria Drug 2018 TERMINATED Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity Broad Institute,Eisai Co., Ltd. $5,368,224 Details
Preclinical Drug Preclinical development Malaria Drug 2019 ACTIVE Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $6,828,394 Details
Preclinical Drug Preclinical development Malaria Drug 2019 ACTIVE Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria University of Kentucky,Eisai Co., Ltd. $5,590,091 Details
Preclinical Drug Lead Optimization Malaria Drug 2020 ACTIVE Structured-based approach to develop a novel mechanism-of-action antimalarial with multistage activity Broad Institute,Eisai Co., Ltd.,The Scripps Research Institute,International Centre for Genetic Engineering and Biotechnology $4,127,236 Details
Preclinical Drug Lead Optimization Malaria Drug 2020 TERMINATED Optimisation of multistage inhibitors of Plasmodium falciparum lysyl t-RNA synthetase for the treatment of malaria University of Dundee,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $3,538,738 Details
Preclinical Drug Lead Optimization Malaria Drug 2021 ACTIVE Preclinical development of a monoclonal antibody to prevent P. falciparum malaria PATH,Eisai Co., Ltd.,Ehime University,GlaxoSmithKline plc. $5,386,616 Details
Preclinical Vaccine Lead Optimization Malaria Vaccine 2015 COMPLETE Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax The University of Florida,CellFree Sciences Co. Ltd.,Infectious Disease Research Institute $419,285 Details
Preclinical Vaccine Preclinical Development Malaria Vaccine 2017 COMPLETE Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0 The University of Florida,CellFree Sciences Co. Ltd.,Ology Bioservices Inc.,Hamamatsu Pharma Research,Infectious Disease Research Institute,Centre Pasteur du Cameroun (CPC) $3,484,217 Details
Preclinical Vaccine Lead Optimization Malaria Vaccine 2018 COMPLETE Further development of a new asexual blood-stage malaria vaccine candidate European Vaccine Initiative (EVI),Ehime University,iBET $930,571 Details
Preclinical Vaccine Preclinical Development Malaria Vaccine 2019 COMPLETE Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant PATH,Sumitomo Dainippon Pharma Co., Ltd.,Ehime University $5,007,283 Details
Preclinical Vaccine Preclinical Development Malaria Vaccine 2021 ACTIVE Clinical development of placental malaria vaccine candidates European Vaccine Initiative (EVI),Ehime University,University of Copenhagen (UCPH) ,Institut national de la santé et de la recherche médicale,Groupe de Recherche Action en Santé (GRAS),Noguchi Memorial Institute for Medical Research,Institut de recherche pour le développement $4,692,924 Details
Preclinical Drug Lead Optimization Tuberculosis Drug 2017 ACTIVE Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis Broad Institute,Eisai Co., Ltd.,Colorado State University,The University of Chicago,The Global Alliance for TB Drug Development $2,003,324 Details
Preclinical Vaccine Lead Optimization Tuberculosis Vaccine 2013 TERMINATED Development of rhPIV2 as a Potential New TB Vaccine Candidate National Institutes of Biomedical Innovation, Health and Nutrition,Aeras $5,649,620 Details
Preclinical Vaccine Lead Optimization Tuberculosis Vaccine 2013 TERMINATED Development of recombinant hPIV2 virus vector as a new TB vaccine National Institutes of Biomedical Innovation, Health and Nutrition,Aeras $700,000 Details
Preclinical Drug Lead Optimization NTD (Lymphatic filariasis / Onchocerciasis) Drug 2013 COMPLETE Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates Liverpool School of Tropical Medicine,Eisai Co., Ltd.,University of Liverpool $1,093,166 Details
Preclinical Drug Lead Optimization NTD (Leishmaniasis) Drug 2014 COMPLETE Lead optimization of the aminopyrazole series for visceral leishmaniasis Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited $4,022,552 Details
Preclinical Drug Lead Optimization NTD (Soil-transmitted helminthiasis) Drug 2015 COMPLETE Cry5B consortium for soil-transmitted helminths PATH,Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School $1,002,996 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2015 COMPLETE Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis GeneDesign, Inc,Drugs for Neglected Diseases initiative $687,715 Details
Preclinical Drug Preclinical development NTD (Dengue) Drug 2016 COMPLETE Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) $5,348,894 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2016 COMPLETE Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis GeneDesign, Inc,Drugs for Neglected Diseases initiative $4,918,672 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2017 TERMINATED Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited $6,047,757 Details
Preclinical Drug Preclinical development NTD (Dengue) Drug 2018 COMPLETE Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN) $4,892,737 Details
Preclinical Drug Preclinical development NTD (Lymphatic filariasis / Onchocerciasis) Drug 2019 ACTIVE Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug Liverpool School of Tropical Medicine,Eisai Co., Ltd.,University of Liverpool $4,335,812 Details
Preclinical Drug Lead Optimization NTD (Chagas disease) Drug 2019 COMPLETE Lead optimization of a candidate series active against Chagas Disease Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative $4,318,565 Details
Preclinical Drug Preclinical development NTD (Leishmaniasis) Drug 2020 ACTIVE Preclinical development of DNDI-6174, a drug candidate for leishmaniasis Drugs for Neglected Diseases initiative,Eisai Co., Ltd. $6,122,938 Details
Preclinical Drug Lead Optimization NTD (Leishmaniasis) Drug 2020 ACTIVE Lead optimization and preclinical candidate selection from the NTD Drug Discovery Booster series S07 for visceral leishmaniasis Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited $2,257,442 Details
Preclinical Drug Preclinical development NTD (Onchocerciasis) Drug 2022 ACTIVE Preclinical development of DNDI-6166 (or CC1076166) a selective macrofilaricide for the treatment of river blindness Drugs for Neglected Diseases initiative,University Hospital of Bonn (UKB), BoZo Research - ITR,Mahidol Oxford Tropical Medicine Research Unit (MORU) $300,000 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2014 COMPLETE Development of a Live Attenuated Tetravalent Dengue Vaccine The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University $3,450,276 Details
Preclinical Vaccine Preclinical Development NTD (Chagas disease) Vaccine 2014 COMPLETE Adjuvant Technologies to Advance Chagas Disease Vaccine Development Sabin Vaccine Institute,Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras $2,000,000 Details
Preclinical Vaccine Lead Optimization NTD (Leishmaniasis) Vaccine 2015 COMPLETE Live attenuated prophylactic vaccine for leishmaniasis The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University $1,832,967 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2015 COMPLETE Preclinical development of MVDVax, a new dengue vaccine European Vaccine Initiative (EVI),Institut Pasteur,Institute of Tropical Medicine (NEKKEN) Nagasaki University $612,902 Details
Preclinical Vaccine Preclinical Development NTD (Leishmaniasis) Vaccine 2016 COMPLETE Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis European Vaccine Initiative (EVI),Mologen ,Charité –Universitätsmedizin Berlin,London School of Hygiene and Tropical Medicine(LSHTM),Nagasaki University $4,096,664 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2016 COMPLETE Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes VLP Therapeutics,National Institute of Infectious Diseases,Institute of Tropical Medicine (NEKKEN) Nagasaki University $986,540 Details
Preclinical Vaccine Preclinical Development NTD (Dengue) Vaccine 2018 ACTIVE The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine VLP Therapeutics,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,Johns Hopkins University,Latham BioPharm Group $4,422,091 Details
Preclinical Vaccine Lead Optimization NTD (Leishmaniasis) Vaccine 2018 ACTIVE Live attenuated prophylactic vaccine for leishmaniasis The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University $3,998,989 Details
Preclinical Vaccine Preclinical Development NTD (Leishmaniasis) Vaccine 2018 COMPLETE Immune therapy to prevent VL complications Infectious Disease Research Institute,University of Tokyo,International Center for Diarrheal Disease Research Bangladesh $558,315 Details
Preclinical Vaccine Lead Optimization NTD (Chagas disease) Vaccine 2019 ACTIVE Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease. The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University $1,097,927 Details
Clinical Drug Clinical Phase2 Malaria Drug 2013 COMPLETE Development of DSM265 as a long acting antimalarial compound Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $2,538,796 Details
Clinical Drug Clinical Phase1 Malaria Drug 2014 COMPLETE Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439 Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $1,290,883 Details
Clinical Drug Clinical Phase2 Malaria Drug 2015 COMPLETE Commercial formulation development of DSM265 Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited $1,905,341 Details
Clinical Drug Clinical Phase2 Malaria Drug 2016 COMPLETE Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria University of Kentucky,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV) $4,500,001 Details
Clinical Drug Clinical Phase2 Malaria Drug 2016 COMPLETE Formulation Optimization Work on DSM265 Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV) $1,589,999 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2013 COMPLETE Clinical Development of BK-SE36/CpG Malaria Vaccine Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda $714,500 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2014 COMPLETE Clinical development of the BK-SE36 malaria vaccine candidate European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP) $999,999 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2016 COMPLETE Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Medical Center for Translational Research (MTR), Osaka University Hospital,Nobelpharma Co., Ltd.,Institut de Recherche en Sciences de la Santé (IRSS) $2,781,588 Details
Clinical Vaccine Phase1 Clinical Development Malaria Vaccine 2019 COMPLETE Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS) $1,870,777 Details
Clinical Vaccine Phase2 Clinical Development Malaria Vaccine 2020 ACTIVE First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 The University of Florida,Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),University of Tübingen (UKT) ,Centre de Recherches Médicales de Lambaréné (CERMEL) ,CellFree Sciences Co. Ltd. $6,486,223 Details
Clinical Diagnostic Product Validation Malaria Diagnostic 2015 COMPLETE Development of a fully automated malaria diagnostic system and field evaluation for practical use Panasonic Corporation,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University $964,500 Details
Clinical Diagnostic Product Development Malaria Diagnostic 2019 COMPLETE Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1) The University of Florida,CellFree Sciences Co. Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,ERADA Technology Alliance, Ltd. $1,382,696 Details
Clinical Vaccine Phase2 Clinical Development Tuberculosis Vaccine 2015 COMPLETE DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”) Geisel School of Medicine at Dartmouth,Muhimbili University of Health and Allied Sciences (MUHAS),Tokyo Medical and Dental University $1,423,590 Details
Clinical Diagnostic Product Validation Tuberculosis Diagnostic 2015 COMPLETE Highly Sensitive POC TB-LAM Rapid Diagnostic Test Foundation for Innovative New Diagnostics (FIND),Fujifilm Corporation $2,160,577 Details
Clinical Diagnostic Product Validation Tuberculosis Diagnostic 2017 COMPLETE Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test Foundation for Innovative New Diagnostics (FIND),Fujifilm Corporation $4,217,169 Details
Clinical Diagnostic Product Validation Tuberculosis Diagnostic 2020 COMPLETE Product Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis Biopromic AB,Asahi Kasei Corporation $2,266,257 Details
Clinical Diagnostic Product Development Tuberculosis Diagnostic 2021 ACTIVE Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial) Research Institute of Tuberculosis ,Acoustic Innovations (AI),Institute of Tropical Medicine (ITM),Center for Health Promotion and Research (CHPR) $833,738 Details
Clinical Drug Clinical Phase2 NTD (Chagas disease) Drug 2013 COMPLETE A new treatment for Chagas disease Drugs for Neglected Diseases initiative,Eisai Co., Ltd. $3,840,892 Details
Clinical Drug Clinical Phase1 NTD (Schistosomiasis) Drug 2013 COMPLETE Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis Lygature,Astellas Pharma Inc.,Farmanguinhos,Simcyp Limited,Swiss Tropical and Public Health Institute,Merck KGaA $1,864,898 Details
Clinical Drug Clinical Phase2 NTD (Schistosomiasis) Drug 2014 COMPLETE Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis Lygature,Astellas Pharma Inc.,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Farmanguinhos $4,856,513 Details
Clinical Drug Clinical Phase3 NTD (Schistosomiasis) Drug 2016 COMPLETE Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children Lygature,Astellas Pharma Inc.,Merck KGaA,Swiss Tropical and Public Health Institute,Farmanguinhos,Simcyp Limited,Schistosomiasis Control Initiative (SCI) $4,679,698 Details
Clinical Drug Clinical Phase2 NTD (Mycetoma) Drug 2017 ACTIVE Mycetoma Treatment, Fosravuconazole Clinical Trial Eisai Co., Ltd.,Drugs for Neglected Diseases initiative $2,526,217 Details
Clinical Drug Registration NTD (Schistosomiasis) Drug 2018 ACTIVE Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation Lygature,Merck KGaA,Astellas Pharma Inc.,Swiss Tropical and Public Health Institute,Farmanguinhos,Schistosomiasis Control Initiative (SCI),Université Félix Houphouët Boigny (UFHB),Kenya Medical Research Institute (KEMRI-CGHR) $4,523,295 Details
Clinical Drug Clinical Phase1 NTD (Leishmaniasis) Drug 2020 ACTIVE Clinical development of CpG-D35 for combined treatment of cutaneous leishmaniasis Drugs for Neglected Diseases initiative,University of Tokyo,Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign) $6,923,997 Details
Clinical Drug Registration NTD (Schistosomiasis) Drug 2020 ACTIVE Adoption of Levo-Praziquantel 150mg for schistosomiasis by endemic countries Lygature,Swiss Tropical and Public Health Institute,SCI Foundation,Merck KGaA,Astellas Pharma Inc.,Klinikum rechts der Isar der Technischen Universität München, Department of Neurology (MRI),Kenya Medical Research Institute (KEMRI-CGHR),Université Félix Houphouët Boigny (UFHB) $2,622,542 Details
Clinical Drug Clinical Phase2 NTD (Lymphatic filariasis / Onchocerciasis) Drug 2022 ACTIVE Phase II Clinical Development of AWZ1066S, a Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug Eisai Co., Ltd.,Liverpool School of Tropical Medicine,University of Liverpool,University of Buea (UoB) ,University Hospital of Bonn (UKB) $7,960,044 Details
Clinical Drug Registration NTD (Mycetoma) Drug 2022 ACTIVE Fosravuconazole treatment in eumycetoma: corroborating study outcomes, preparing for access Drugs for Neglected Diseases initiative,Eisai Co., Ltd. $2,964,666 Details
Clinical Diagnostic Product Development NTD (Leishmaniasis) Diagnostic 2019 ACTIVE Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity The Ohio State University,McGill University ,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,U.S. Food and Drug Administration $2,257,699 Details
Clinical Diagnostic Product Development NTD (Schistosomiasis) Diagnostic 2020 ACTIVE A schistosomiasis rapid diagnostic test to support control programmes in monitoring treatment impact and reassessment mapping Foundation for Innovative New Diagnostics (FIND),Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Merck KGaA $3,733,973 Details
Clinical Diagnostic Product Development NTD (Buruli ulcer) Diagnostic 2020 ACTIVE A Buruli ulcer mycolactone (BU-MYCOLAC) rapid diagnostic test to enhance early diagnosis and treatment Foundation for Innovative New Diagnostics (FIND),Nagasaki University,Swiss Tropical and Public Health Institute,Drugs and Diagnostics for Tropical Diseases $1,836,107 Details
Clinical Diagnostic Product Validation NTD (Chagas disease) Diagnostic 2020 ACTIVE Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease Barcelona Institute for Global Health (ISGLOBAL) ,Eiken Chemical Co., Ltd.,Nagasaki University,Fundacion Mundo Sano,Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES) ,Centro para el Desarrollo de Investigación Científica (CEDIC) ,Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (CONICET-INGEBI),AI Biosciences Inc. $1,471,273 Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $104,264
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $73,940
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Kitasato Institute,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $570
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $241,372
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Institute of Microbial Chemistry,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $11,286
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Mitsubishi Tanabe Pharma Corporation,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $186,420
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Sumitomo Dainippon Pharma Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $137,883
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Design and Cost-effective de novo Synthesis of Aza-artemisinins
  • Partner: Hokkaido University,Kitasato Institute,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $60,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Identification of lead compounds for anti-Malarial agent
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $636,941
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Hit-to-Lead Discovery for New Anti-malarials in Collaboration between MMV and Eisai
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $779,760
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Antimalarial hits from whole cell screening
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $764,033
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Proteasome inhibitors as new potent resistance-­reversing antimalarials
  • Partner: The University of Melbourne,Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $297,133
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Op Bio Factory Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $68,400
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Eisai
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $750,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Mitsubishi Tanabe malaria Hit-to-Lead
  • Partner: Medicines for Malaria Venture (MMV),Mitsubishi Tanabe Pharma Corporation
  • Awarded Amount: $618,222
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarias between MMV and Takeda
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $483,360
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited,The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute
  • Awarded Amount: $461,245
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo Dainippon Pharma
  • Partner: Medicines for Malaria Venture (MMV),Sumitomo Dainippon Pharma Co., Ltd.
  • Awarded Amount: $445,500
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Astellas Pharma Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $65,836
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $49,500
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $528,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Screening Program
  • Partner: Medicines for Malaria Venture (MMV),University of Tokyo
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Development of nucleoside sulfamates as novel antimalarials
  • Partner: The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,016,129
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Proteasome inhibitors as new potent antimalarials
  • Partner: The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute,Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $526,140
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Screening project between Takeda and MMV
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $41,962
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Hit-to-lead development of new antimalarial compounds from DDI library
  • Partner: University of Tokyo,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,167,442
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Pioneering antisense oligonucleotides as long-acting malaria prophylactics
  • Partner: University of California, San Diego (UCSD),Eisai Co., Ltd.
  • Awarded Amount: $922,972
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Screening Program
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited,Eisai Co., Ltd.,Daiichi Sankyo, Inc.
  • Awarded Amount: $210,936
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Prolyl tRNA Synthetase Inhibitors for New Antimalarials
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $547,268
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $122,013
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Hit-to-Lead development of novel Astellas compounds with antimalarial activity
  • Partner: TCG Lifesciences Private Limited. (TCGLS),Astellas Pharma Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,317,435
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform
  • Partner: National Center for Genetic Engineering and Biotechnology (BIOTEC) ,FIMECS, Inc.
  • Awarded Amount: $838,587
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: A Hit-to-Lead study of screening hits for novel antimalarial compounds
  • Partner: SHIONOGI & CO., LTD.,Nagasaki University,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,323,184
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: Irresistible series as anti-malarial agent
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,307,233
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach
  • Partner: PATH Malaria Vaccine Initiative,Ehime University,CellFree Sciences Co. Ltd.
  • Awarded Amount: $591,396
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate
  • Partner: PATH Malaria Vaccine Initiative,Ehime University
  • Awarded Amount: $766,098
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display
  • Partner: PATH Malaria Vaccine Initiative,Ehime University
  • Awarded Amount: $595,650
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2017
  • Status: 
  • Project: Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator
  • Partner: The Pennsylvania State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Antigen Discovery, Inc.
  • Awarded Amount: $881,900
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Co-delivery of Pfs230C1 and CSP with CoPoP, a versatile, potent liposomal adjuvant system for multistage malaria vaccine
  • Partner: PATH Malaria Vaccine Initiative,Ehime University,University at Buffalo, The State University of New York
  • Awarded Amount: $972,951
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Technology Platform Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity
  • Partner: Mahidol University,Tokyo Medical and Dental University,University of Pennsylvania
  • Awarded Amount: $960,771
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Vaccine Concept Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants
  • Partner: Kanazawa University,Hokkaido University,Jichi Medical University,Toyama University,University of Cambridge
  • Awarded Amount: $526,900
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2020
  • Status: 
  • Project: Evaluation of a malaria vaccine candidate comprised of full-length recombinant CSP formulated with SA-1 adjuvant, using RTS,S/AS01 as a benchmark
  • Partner: PATH,Sumitomo Dainippon Pharma Co., Ltd.,Ehime University
  • Awarded Amount: $999,733
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2021
  • Status: 
  • Project: Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking
  • Partner: Kanazawa University,Hokkaido University,Jichi Medical University,Kyoto University,Toyama University,University of Cambridge,Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)
  • Awarded Amount: $698,170
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Antigen Identification
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2022
  • Status: 
  • Project: Development of a potent Pvs230 mRNA vaccine to block transmission of P. vivax
  • Partner: Mahidol University,Ehime University
  • Awarded Amount: $699,652
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Technical Feasibility
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination
  • Partner: The Walter and Eliza Hall Institute of Medical Research,Proteo-Science Centre, Ehime University,CellFree Sciences Co. Ltd.,Foundation for Innovative New Diagnostics (FIND)
  • Awarded Amount: $993,030
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Towards rapid diagnosis of Plasmodium vivax malaria hypnozoite infection
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Technology, Kumamoto College,Biomedical Primate Research Centre
  • Awarded Amount: $728,830
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Technical Feasibility
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: Towards the rapid diagnosis of malaria hypnozoite infection: feasibility studies
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Biomedical Primate Research Centre,National Institute of Technology, Kumamoto College
  • Awarded Amount: $999,809
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: SHIONOGI & CO., LTD.,The Global Alliance for TB Drug Development
  • Awarded Amount: $105,450
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
  • Awarded Amount: $55,550
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $135,300
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Screening Program
  • Partner: Op Bio Factory Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Hit-to-Lead Development of anti-TB Phenotypic Screening Hits
  • Partner: SHIONOGI & CO., LTD.,The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association,The Global Alliance for TB Drug Development
  • Awarded Amount: $999,720
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Development of Phenotypic Screening Hits against Mycobacterium tuberculosis
  • Partner: Takeda Pharmaceutical Company Limited,The Global Alliance for TB Drug Development
  • Awarded Amount: $792,165
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Chugai Pharmaceutical Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: HYPHAGENESIS INC.,Toyama Prefectural University,The Global Alliance for TB Drug Development
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Mitsubishi Tanabe Pharma Corporation,The Global Alliance for TB Drug Development
  • Awarded Amount: $132,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Sumitomo Dainippon Pharma Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $79,200
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Identification of lead compounds as novel anti‐TB agents
  • Partner: Daiichi Sankyo, Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $908,231
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Host-directed drug targeting against tuberculosis
  • Partner: RIKEN,International Centre for Genetic Engineering and Biotechnology
  • Awarded Amount: $204,990
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Screening Program
  • Partner: Astellas Pharma Inc.,The Global Alliance for TB Drug Development
  • Awarded Amount: $99,986
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Hit-to-Lead Development of Novel anti-TB Natural Products
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $1,192,440
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Screening Program
  • Partner: The Global Alliance for TB Drug Development,Fujifilm Corporation
  • Awarded Amount: $110,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Hit-to-Lead Development of Phenotypic and Mechanism-based Screen Hits
  • Partner: The Global Alliance for TB Drug Development,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $1,112,058
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Hit-to-Lead Development of Phenotypic Screening Hits
  • Partner: The Global Alliance for TB Drug Development,Chugai Pharmaceutical Co., Ltd.
  • Awarded Amount: $953,159
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Identification of novel dual-acting bactericidal drug targets against Mycobacterium tuberculosis
  • Partner: Fujita Health University ,Research Institute of Tuberculosis ,Nagoya University,Hokkaido University,Harvard University,University of Minnesota
  • Awarded Amount: $974,619
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Hit-to-Lead Development of Hits Identified in the Phenotypic Screening against Mycobacterium tuberculosis (Mtb)
  • Partner: The Global Alliance for TB Drug Development,Astellas Pharma Inc.
  • Awarded Amount: $801,363
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $118,300
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: Screening project between Daiichi Sankyo RD Novare and TB Alliance
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,The Global Alliance for TB Drug Development
  • Awarded Amount: $152,970
Details
  • Development Stage: Discovery
  • Current Stage: Vaccine Vaccine Concept Development
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Development of a new mucosal vaccine for Tuberculosis using antibody engineering
  • Partner: Universiti Sains Malaysia,University of Tokyo,Instituto de Nutricion “Salvador Zubiran”,Universidad de Concepcion
  • Awarded Amount: $373,561
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2018
  • Status: 
  • Project: Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria.
  • Partner: Asahi Kasei Corporation,Biopromic AB
  • Awarded Amount: $1,000,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease
  • Partner: Broad Institute,Eisai Co., Ltd.
  • Awarded Amount: $500,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $75,582
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Takeda Pharmaceutical Company Limited,Drugs for Neglected Diseases initiative
  • Awarded Amount: $75,582
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Kitasato Institute,Drugs for Neglected Diseases initiative
  • Awarded Amount: $0
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Screening Program
  • Partner: Institute of Microbial Chemistry,Drugs for Neglected Diseases initiative
  • Awarded Amount: $7,558
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $795,437
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $210,050
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Screening Program
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $31,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Targeting bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis and cryptosporidiosis
  • Partner: RIKEN,Structural Genomics Consortium at University of Toronto,The University of Melbourne,McGill University ,Medicines for Malaria Venture (MMV),Drugs for Neglected Diseases initiative
  • Awarded Amount: $982,436
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Identification of lead compounds for Leishmania donovani and/or Trypanosoma cruzi
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $780,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster II
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $549,447
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Neglected Tropical Diseases Drug Discovery Booster III
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.,SHIONOGI & CO., LTD.,Takeda Pharmaceutical Company Limited,Astellas Pharma Inc.
  • Awarded Amount: $1,498,328
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Validation
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Target determination and exploratory research for discovery of new drugs against Chagas disease.
  • Partner: Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Advanced Industrial Science and Technology,High Energy Accelerator Research Organization (KEK),London School of Hygiene and Tropical Medicine(LSHTM)
  • Awarded Amount: $882,350
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare
  • Partner: Drugs for Neglected Diseases initiative,Daiichi Sankyo RD Novare Co., Ltd.
  • Awarded Amount: $119,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Screening project between Mitsubishi Tanabe and DNDi
  • Partner: Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative
  • Awarded Amount: $150,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Target validation and AI-guided identification of Trypanosoma cruzi phosphodiesterase inhibitors for the treatment of Chagas disease
  • Partner: Eisai Co., Ltd.,Universidad Nacional de La Plata (UNLP)
  • Awarded Amount: $710,077
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Screening Program
  • Partner: University of Tokyo,Drugs for Neglected Diseases initiative
  • Awarded Amount: $168,759
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Hit-To-Lead development for Neglected Tropical Diseases
  • Partner: Mitsubishi Tanabe Pharma Corporation,Drugs for Neglected Diseases initiative
  • Awarded Amount: $1,170,663
Details
  • Development Stage: Discovery
  • Current Stage: Drug Lead Identification
  • Disease: NTD (Soil-transmitted helminthiasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Cry5B optimization for Trichuris - whipworm
  • Partner: PATH,Kao Corporation,University of Massachusetts Medical School
  • Awarded Amount: $923,020
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease / Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Screening Program
  • Partner: Daiichi Sankyo RD Novare Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $80,000
Details
  • Development Stage: Discovery
  • Current Stage: Drug Target Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Autophagy as a novel drug-development target for Chagas disease
  • Partner: National Institute of Advanced Industrial Science and Technology,Drugs for Neglected Diseases initiative
  • Awarded Amount: $989,200
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Screening project between Daiichi Sankyo Company Limited and DNDi
  • Partner: Drugs for Neglected Diseases initiative,Daiichi Sankyo, Inc.
  • Awarded Amount: $109,763
Details
  • Development Stage: Discovery
  • Current Stage: Drug Hit Identification
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Screening project between Takeda Pharmaceutical Company Ltd. and DNDi
  • Partner: Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $89,946
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Development Feasibility
  • Disease: NTD (Schistosomiasis)
  • Intervention: Diagnostic
  • RFP Year: 2014
  • Status: 
  • Project: Development of a sensitive and specific point-of-care diagnostics for Asian zoonotic schistosomiasis
  • Partner: National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine,Graduate School of Agricultural and Life Sciences, The University of Tokyo,InBios International, Inc.,University of the Philippines
  • Awarded Amount: $779,036
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: NTD (Schistosomiasis)
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine
  • Partner: Lygature,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center
  • Awarded Amount: $763,890
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: NTD (Mycetoma)
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma
  • Partner: RIKEN,Erasmus University Medical Center,Hospital General de Mexico,Mycetoma Research Centre (MRC), University of Khartoum
  • Awarded Amount: $285,937
Details
  • Development Stage: Discovery
  • Current Stage: Diagnostic Concept Development
  • Disease: NTD (Buruli ulcer)
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: Development of ‘all-in-one’ diagnostic kit for Buruli ulcer using lateral flow DNA-chromatography
  • Partner: Teikyo University,Keio University School of Medicine,TBA Co., Ltd.,Fasmac Co., Ltd.,Raoul Follereau Institute Côte d’Ivoire,Institut Pasteur de Côte d'Ivoire,Hope Commission International,Nagasaki University
  • Awarded Amount: $895,584
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development of ELQ300 as a long acting antimalarial
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $560,000
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4
  • Partner: St. Jude Children’s Research Hospital,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $3,768,922
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Lead optimization of a novel mechanism-of-action antimalarial
  • Partner: Broad Institute,Eisai Co., Ltd.
  • Awarded Amount: $2,997,525
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: E209 a tetraoxane based rapidly acting antimalarial – candidate selection
  • Partner: Liverpool School of Tropical Medicine,University of Liverpool,Eisai Co., Ltd.
  • Awarded Amount: $207,753
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Development of a novel mechanism-of-action antimalarial drug with multistage activity
  • Partner: Broad Institute,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,999,993
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: DSM421 Clinical Development up to phase IIa GO
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $7,499,822
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Identification of pre-clinical candidate as an anti-malarial agent
  • Partner: Daiichi Sankyo, Inc.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,761,309
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Lead optimization of potent Gwt1p inhibitors toward a new antimalarial drug with a novel mechanism of action
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $2,639,670
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria
  • Partner: Broad Institute,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $4,214,187
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Mitsubishi Tanabe Lead Optimization of Anti-Malarials
  • Partner: Medicines for Malaria Venture (MMV),Mitsubishi Tanabe Pharma Corporation
  • Awarded Amount: $1,922,475
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity
  • Partner: Broad Institute,Eisai Co., Ltd.
  • Awarded Amount: $5,368,224
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action
  • Partner: Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $6,828,394
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria
  • Partner: University of Kentucky,Eisai Co., Ltd.
  • Awarded Amount: $5,590,091
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Structured-based approach to develop a novel mechanism-of-action antimalarial with multistage activity
  • Partner: Broad Institute,Eisai Co., Ltd.,The Scripps Research Institute,International Centre for Genetic Engineering and Biotechnology
  • Awarded Amount: $4,127,236
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Optimisation of multistage inhibitors of Plasmodium falciparum lysyl t-RNA synthetase for the treatment of malaria
  • Partner: University of Dundee,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $3,538,738
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2021
  • Status: 
  • Project: Preclinical development of a monoclonal antibody to prevent P. falciparum malaria
  • Partner: PATH,Eisai Co., Ltd.,Ehime University,GlaxoSmithKline plc.
  • Awarded Amount: $5,386,616
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P.falciparum and P. vivax
  • Partner: The University of Florida,CellFree Sciences Co. Ltd.,Infectious Disease Research Institute
  • Awarded Amount: $419,285
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2017
  • Status: 
  • Project: Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0
  • Partner: The University of Florida,CellFree Sciences Co. Ltd.,Ology Bioservices Inc.,Hamamatsu Pharma Research,Infectious Disease Research Institute,Centre Pasteur du Cameroun (CPC)
  • Awarded Amount: $3,484,217
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Further development of a new asexual blood-stage malaria vaccine candidate
  • Partner: European Vaccine Initiative (EVI),Ehime University,iBET
  • Awarded Amount: $930,571
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant
  • Partner: PATH,Sumitomo Dainippon Pharma Co., Ltd.,Ehime University
  • Awarded Amount: $5,007,283
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2021
  • Status: 
  • Project: Clinical development of placental malaria vaccine candidates
  • Partner: European Vaccine Initiative (EVI),Ehime University,University of Copenhagen (UCPH) ,Institut national de la santé et de la recherche médicale,Groupe de Recherche Action en Santé (GRAS),Noguchi Memorial Institute for Medical Research,Institut de recherche pour le développement
  • Awarded Amount: $4,692,924
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis
  • Partner: Broad Institute,Eisai Co., Ltd.,Colorado State University,The University of Chicago,The Global Alliance for TB Drug Development
  • Awarded Amount: $2,003,324
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Development of rhPIV2 as a Potential New TB Vaccine Candidate
  • Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
  • Awarded Amount: $5,649,620
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Development of recombinant hPIV2 virus vector as a new TB vaccine
  • Partner: National Institutes of Biomedical Innovation, Health and Nutrition,Aeras
  • Awarded Amount: $700,000
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Lymphatic filariasis / Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates
  • Partner: Liverpool School of Tropical Medicine,Eisai Co., Ltd.,University of Liverpool
  • Awarded Amount: $1,093,166
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Lead optimization of the aminopyrazole series for visceral leishmaniasis
  • Partner: Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $4,022,552
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Soil-transmitted helminthiasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Cry5B consortium for soil-transmitted helminths
  • Partner: PATH,Meiji Seika Pharma Co., Ltd.,University of Massachusetts Medical School
  • Awarded Amount: $1,002,996
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis
  • Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
  • Awarded Amount: $687,715
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Dengue)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
  • Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
  • Awarded Amount: $5,348,894
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis
  • Partner: GeneDesign, Inc,Drugs for Neglected Diseases initiative
  • Awarded Amount: $4,918,672
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis
  • Partner: Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $6,047,757
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Dengue)
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes
  • Partner: Chugai Pharmaceutical Co., Ltd.,A∗STAR′s Singapore Immunology Network (SIgN)
  • Awarded Amount: $4,892,737
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Lymphatic filariasis / Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
  • Partner: Liverpool School of Tropical Medicine,Eisai Co., Ltd.,University of Liverpool
  • Awarded Amount: $4,335,812
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2019
  • Status: 
  • Project: Lead optimization of a candidate series active against Chagas Disease
  • Partner: Daiichi Sankyo, Inc.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $4,318,565
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Preclinical development of DNDI-6174, a drug candidate for leishmaniasis
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.
  • Awarded Amount: $6,122,938
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Lead optimization and preclinical candidate selection from the NTD Drug Discovery Booster series S07 for visceral leishmaniasis
  • Partner: Drugs for Neglected Diseases initiative,Takeda Pharmaceutical Company Limited
  • Awarded Amount: $2,257,442
Details
  • Development Stage: Preclinical
  • Current Stage: Drug Preclinical development
  • Disease: NTD (Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: Preclinical development of DNDI-6166 (or CC1076166) a selective macrofilaricide for the treatment of river blindness
  • Partner: Drugs for Neglected Diseases initiative,University Hospital of Bonn (UKB), BoZo Research - ITR,Mahidol Oxford Tropical Medicine Research Unit (MORU)
  • Awarded Amount: $300,000
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Development of a Live Attenuated Tetravalent Dengue Vaccine
  • Partner: The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),Mahidol University
  • Awarded Amount: $3,450,276
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Chagas disease)
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Adjuvant Technologies to Advance Chagas Disease Vaccine Development
  • Partner: Sabin Vaccine Institute,Eisai Co., Ltd.,Baylor College of Medicine (BCM),Aeras
  • Awarded Amount: $2,000,000
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Live attenuated prophylactic vaccine for leishmaniasis
  • Partner: The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,McGill University
  • Awarded Amount: $1,832,967
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: Preclinical development of MVDVax, a new dengue vaccine
  • Partner: European Vaccine Initiative (EVI),Institut Pasteur,Institute of Tropical Medicine (NEKKEN) Nagasaki University
  • Awarded Amount: $612,902
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis
  • Partner: European Vaccine Initiative (EVI),Mologen ,Charité –Universitätsmedizin Berlin,London School of Hygiene and Tropical Medicine(LSHTM),Nagasaki University
  • Awarded Amount: $4,096,664
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Development of novel dengue virus-like particle (VLP) vaccines against all four serotypes
  • Partner: VLP Therapeutics,National Institute of Infectious Diseases,Institute of Tropical Medicine (NEKKEN) Nagasaki University
  • Awarded Amount: $986,540
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Dengue)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: The development and production of cGMP lots of a novel tetravalent dengue virus-like particle (VLP) vaccine
  • Partner: VLP Therapeutics,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,National Institute of Infectious Diseases,Johns Hopkins University,Latham BioPharm Group
  • Awarded Amount: $4,422,091
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Live attenuated prophylactic vaccine for leishmaniasis
  • Partner: The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,McGill University
  • Awarded Amount: $3,998,989
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Preclinical Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Vaccine
  • RFP Year: 2018
  • Status: 
  • Project: Immune therapy to prevent VL complications
  • Partner: Infectious Disease Research Institute,University of Tokyo,International Center for Diarrheal Disease Research Bangladesh
  • Awarded Amount: $558,315
Details
  • Development Stage: Preclinical
  • Current Stage: Vaccine Lead Optimization
  • Disease: NTD (Chagas disease)
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Optimization and pre-clinical development of a Trypanosoma cruzi Cyp19 knock-out strain as a live vaccine for Chagas disease.
  • Partner: The Ohio State University,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Ohio University
  • Awarded Amount: $1,097,927
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development of DSM265 as a long acting antimalarial compound
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $2,538,796
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase1
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $1,290,883
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2015
  • Status: 
  • Project: Commercial formulation development of DSM265
  • Partner: Medicines for Malaria Venture (MMV),Takeda Pharmaceutical Company Limited
  • Awarded Amount: $1,905,341
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Phase 2 Trial of SJ733, a Novel PfATP4 Inhibitor for Malaria
  • Partner: University of Kentucky,Eisai Co., Ltd.,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $4,500,001
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: Malaria
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Formulation Optimization Work on DSM265
  • Partner: Takeda Pharmaceutical Company Limited,Medicines for Malaria Venture (MMV)
  • Awarded Amount: $1,589,999
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2013
  • Status: 
  • Project: Clinical Development of BK-SE36/CpG Malaria Vaccine
  • Partner: Research Institute for Microbial Diseases (RIMD), Osaka University,Gulu University, Uganda
  • Awarded Amount: $714,500
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2014
  • Status: 
  • Project: Clinical development of the BK-SE36 malaria vaccine candidate
  • Partner: European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
  • Awarded Amount: $999,999
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2016
  • Status: 
  • Project: Clinical Development of BK-SE36/CpG Malaria Vaccine: safety evaluation of BK-SE36/CpG in the malaria endemic population
  • Partner: European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Medical Center for Translational Research (MTR), Osaka University Hospital,Nobelpharma Co., Ltd.,Institut de Recherche en Sciences de la Santé (IRSS)
  • Awarded Amount: $2,781,588
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase1 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2019
  • Status: 
  • Project: Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG
  • Partner: European Vaccine Initiative (EVI),Research Institute for Microbial Diseases (RIMD), Osaka University,Nobelpharma Co., Ltd.,Groupe de Recherche Action en Santé (GRAS)
  • Awarded Amount: $1,870,777
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase2 Clinical Development
  • Disease: Malaria
  • Intervention: Vaccine
  • RFP Year: 2020
  • Status: 
  • Project: First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1
  • Partner: The University of Florida,Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign),University of Tübingen (UKT) ,Centre de Recherches Médicales de Lambaréné (CERMEL) ,CellFree Sciences Co. Ltd.
  • Awarded Amount: $6,486,223
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Development of a fully automated malaria diagnostic system and field evaluation for practical use
  • Partner: Panasonic Corporation,Juntendo University,Kenya Medical Research Institute (KEMRI-CGHR),Malaria No More Japan (MNMJ),National Institute of Advanced Industrial Science and Technology,Institute of Tropical Medicine (NEKKEN) Nagasaki University
  • Awarded Amount: $964,500
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Development
  • Disease: Malaria
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: Commercial Development of a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART-1)
  • Partner: The University of Florida,CellFree Sciences Co. Ltd.,Frontier Institute Co., Ltd.,Oasis Diagnostics Corp.,ERADA Technology Alliance, Ltd.
  • Awarded Amount: $1,382,696
Details
  • Development Stage: Clinical
  • Current Stage: Vaccine Phase2 Clinical Development
  • Disease: Tuberculosis
  • Intervention: Vaccine
  • RFP Year: 2015
  • Status: 
  • Project: DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (“DAR-PIA”)
  • Partner: Geisel School of Medicine at Dartmouth,Muhimbili University of Health and Allied Sciences (MUHAS),Tokyo Medical and Dental University
  • Awarded Amount: $1,423,590
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2015
  • Status: 
  • Project: Highly Sensitive POC TB-LAM Rapid Diagnostic Test
  • Partner: Foundation for Innovative New Diagnostics (FIND),Fujifilm Corporation
  • Awarded Amount: $2,160,577
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2017
  • Status: 
  • Project: Fujifilm SILVAMP TB LAM – A Sensitive point-of-care Tuberculosis Test
  • Partner: Foundation for Innovative New Diagnostics (FIND),Fujifilm Corporation
  • Awarded Amount: $4,217,169
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: Product Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis
  • Partner: Biopromic AB,Asahi Kasei Corporation
  • Awarded Amount: $2,266,257
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Development
  • Disease: Tuberculosis
  • Intervention: Diagnostic
  • RFP Year: 2021
  • Status: 
  • Project: Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial)
  • Partner: Research Institute of Tuberculosis ,Acoustic Innovations (AI),Institute of Tropical Medicine (ITM),Center for Health Promotion and Research (CHPR)
  • Awarded Amount: $833,738
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Chagas disease)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: A new treatment for Chagas disease
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.
  • Awarded Amount: $3,840,892
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase1
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2013
  • Status: 
  • Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
  • Partner: Lygature,Astellas Pharma Inc.,Farmanguinhos,Simcyp Limited,Swiss Tropical and Public Health Institute,Merck KGaA
  • Awarded Amount: $1,864,898
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2014
  • Status: 
  • Project: Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis
  • Partner: Lygature,Astellas Pharma Inc.,Merck KGaA,Simcyp Limited,Swiss Tropical and Public Health Institute,Farmanguinhos
  • Awarded Amount: $4,856,513
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase3
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2016
  • Status: 
  • Project: Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis in preschool-aged children
  • Partner: Lygature,Astellas Pharma Inc.,Merck KGaA,Swiss Tropical and Public Health Institute,Farmanguinhos,Simcyp Limited,Schistosomiasis Control Initiative (SCI)
  • Awarded Amount: $4,679,698
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Mycetoma)
  • Intervention: Drug
  • RFP Year: 2017
  • Status: 
  • Project: Mycetoma Treatment, Fosravuconazole Clinical Trial
  • Partner: Eisai Co., Ltd.,Drugs for Neglected Diseases initiative
  • Awarded Amount: $2,526,217
Details
  • Development Stage: Clinical
  • Current Stage: Drug Registration
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2018
  • Status: 
  • Project: Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation
  • Partner: Lygature,Merck KGaA,Astellas Pharma Inc.,Swiss Tropical and Public Health Institute,Farmanguinhos,Schistosomiasis Control Initiative (SCI),Université Félix Houphouët Boigny (UFHB),Kenya Medical Research Institute (KEMRI-CGHR)
  • Awarded Amount: $4,523,295
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase1
  • Disease: NTD (Leishmaniasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Clinical development of CpG-D35 for combined treatment of cutaneous leishmaniasis
  • Partner: Drugs for Neglected Diseases initiative,University of Tokyo,Ajinomoto Bio-Pharma Services, GeneDesign (GeneDesign)
  • Awarded Amount: $6,923,997
Details
  • Development Stage: Clinical
  • Current Stage: Drug Registration
  • Disease: NTD (Schistosomiasis)
  • Intervention: Drug
  • RFP Year: 2020
  • Status: 
  • Project: Adoption of Levo-Praziquantel 150mg for schistosomiasis by endemic countries
  • Partner: Lygature,Swiss Tropical and Public Health Institute,SCI Foundation,Merck KGaA,Astellas Pharma Inc.,Klinikum rechts der Isar der Technischen Universität München, Department of Neurology (MRI),Kenya Medical Research Institute (KEMRI-CGHR),Université Félix Houphouët Boigny (UFHB)
  • Awarded Amount: $2,622,542
Details
  • Development Stage: Clinical
  • Current Stage: Drug Clinical Phase2
  • Disease: NTD (Lymphatic filariasis / Onchocerciasis)
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: Phase II Clinical Development of AWZ1066S, a Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug
  • Partner: Eisai Co., Ltd.,Liverpool School of Tropical Medicine,University of Liverpool,University of Buea (UoB) ,University Hospital of Bonn (UKB)
  • Awarded Amount: $7,960,044
Details
  • Development Stage: Clinical
  • Current Stage: Drug Registration
  • Disease: NTD (Mycetoma)
  • Intervention: Drug
  • RFP Year: 2022
  • Status: 
  • Project: Fosravuconazole treatment in eumycetoma: corroborating study outcomes, preparing for access
  • Partner: Drugs for Neglected Diseases initiative,Eisai Co., Ltd.
  • Awarded Amount: $2,964,666
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Development
  • Disease: NTD (Leishmaniasis)
  • Intervention: Diagnostic
  • RFP Year: 2019
  • Status: 
  • Project: Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity
  • Partner: The Ohio State University,McGill University ,Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Gennova Biopharmaceuticals Ltd.,U.S. Food and Drug Administration
  • Awarded Amount: $2,257,699
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Development
  • Disease: NTD (Schistosomiasis)
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: A schistosomiasis rapid diagnostic test to support control programmes in monitoring treatment impact and reassessment mapping
  • Partner: Foundation for Innovative New Diagnostics (FIND),Institute of Tropical Medicine (NEKKEN) Nagasaki University ,Leiden University Medical Center,Merck KGaA
  • Awarded Amount: $3,733,973
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Development
  • Disease: NTD (Buruli ulcer)
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: A Buruli ulcer mycolactone (BU-MYCOLAC) rapid diagnostic test to enhance early diagnosis and treatment
  • Partner: Foundation for Innovative New Diagnostics (FIND),Nagasaki University,Swiss Tropical and Public Health Institute,Drugs and Diagnostics for Tropical Diseases
  • Awarded Amount: $1,836,107
Details
  • Development Stage: Clinical
  • Current Stage: Diagnostic Product Validation
  • Disease: NTD (Chagas disease)
  • Intervention: Diagnostic
  • RFP Year: 2020
  • Status: 
  • Project: Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease
  • Partner: Barcelona Institute for Global Health (ISGLOBAL) ,Eiken Chemical Co., Ltd.,Nagasaki University,Fundacion Mundo Sano,Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES) ,Centro para el Desarrollo de Investigación Científica (CEDIC) ,Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (CONICET-INGEBI),AI Biosciences Inc.
  • Awarded Amount: $1,471,273
Details